In a precautionary statement about two reports published in the Annals of Internal Medicine, the American Association of Clinical Endocrinologists warned that "misinterpretation ... may cause patients to discontinue needed treatment for diabetes."
In a precautionary statement about two reports published in the Annals of Internal Medicine, the American Association of Clinical Endocrinologists warned that "misinterpretation ... may cause patients to discontinue needed treatment for diabetes."
The two case reports each concern a patient who developed liver dysfunction after recently starting treatment with rosiglitazone (Avandia,® manufactured by SmithKline Beecham) to improve the control of diabetes. The patients recovered after discontinuation of rosiglitazone and showed improvement in their other medical conditions.
The Annals of Internal Medicine authors suggest the liver dysfunction was due to hepatotoxicity related to the use of rosiglitazone, but an AACE spokesperson stated that there might be alternative explanations for the findings. The guidelines for liver function testing for all patients receiving this thiazolodenedione or "glitazone" class of medications remain prudent, as the FDA-approved package inserts suggest.
"These reports must be taken in the context of the risk/benefit profile of the glitazones," said Daniel Einhorn, MD, AACE board of directors member. The class includes rosiglitazone, troglitazone (Parke-Davis' Rezulin®) and pioglitazone (Eli Lilly's and Takeda's Actos®). PR
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.